Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Kempharm Inc (NQ: KMPH )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Feb 28, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 5.690 (8)
Ask (Size) 6.000 (20)
Prev. Close 5.810
Today's Range N/A - N/A
52wk Range N/A - N/A
Shares Outstanding 33,932,639
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
CORRECTION – KemPharm Announces Corporate Name Change to Zevra Therapeutics
From KemPharm
Via GlobeNewswire
KemPharm Announces Corporate Name Change to Zevra Therapeutics
From KemPharm
Via GlobeNewswire

Performance

More News

Read More
This Rare Disease Focused Stock Pipeline Is Underappreciated, Analyst Initiating Coverage Says
Via Benzinga
KemPharm's Earnings: A Preview
Via Benzinga
KemPharm's Lead Prodrug Shows Favorable Safety Profile For Rare Sleeping Disorder
Via Benzinga
Recap: KemPharm Q2 Earnings
Via Benzinga
KemPharm Acquires Battered Orphazyme's Arimoclomol Program For $13M
Via Benzinga
KemPharm's SDX Higher Dose Shows Potential Against Sleep Disorders
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 17, 2022
Via Benzinga
US Stocks Turn Lower; Nasdaq Drops Over 100 Points
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 15, 2022
Via Benzinga
Apple To $220? Here Are 5 Other Price Target Changes For Wednesday
Via Benzinga
Recap: KemPharm Q1 Earnings
Via Benzinga
Earnings Preview For KemPharm
Via Benzinga
The Technology Helping Existing FDA-Approved Drugs Target More Effectively
Via Benzinga
Benzinga Announces This Week's All Access Guests
Via Benzinga
26 Stocks Moving in Monday's Pre-Market Session
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Earnings Scheduled For March 30, 2022
Via Benzinga
KemPharm To Develop KP1077 As Lead SDX Candidate For Chronic Sleep Disorder
Via Benzinga
The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More
Via Benzinga
38 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2022
Via Benzinga
65 Biggest Movers From Yesterday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.